Zizanoic acid is an uncommon sesquiterpene carboxylic acid associated mainly with vetiver root oil rather than with high-impact fragrance odor. The strongest public evidence is for identity, structural history, and repeated occurrence in vetiver chemistry, with newer work focused on selectively isolating the acid from complex vetiver matrices. Direct biological evidence exists but is sparse, mostly older or secondary-source-referenced, so AromaForge should position zizanoic acid primarily as a vetiver chemistry marker and specialty precursor rather than a well-established standalone active.
Chemical identity and composition
PubChem lists zizanoic acid as CID 21764437 with formula C15H22O2 and CAS 16203-25-1, and synonym data also include khusenic acid. A 1973 Tetrahedron paper established zizanoic and epizizanoic acids as vetiver-oil sesquiterpene carboxylic acids, while a 2025 Separations paper confirmed that commercial vetiver oils contain zizanoic acid at less than 10% before selective enrichment and identified it by GC-MS, UHPLC-HRMS, and NMR. In AromaForge oil context, vetted vetiver records currently place it around 1.0% in one India-profile row, 1.6% in a Haiti row, and 5.16% in Madagascar-linked rows.
Aroma and practical use
- Use the recorded faint, low-odor, vetiver-associated descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2025 full-text Separations paper reported that zizanoic acid was selectively isolated from commercial vetiver oils at 84-87% purity using KOH-impregnated silica gel column chromatography, with confirmation by GC-MS, UHPLC-HRMS, and NMR.
A 2025 full-text Separations paper reported that zizanoic acid was selectively isolated from commercial vetiver oils at 84-87% purity using KOH-impregnated silica gel column chromatography, with confirmation by GC-MS, UHPLC-HRMS, and NMR.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The same 2025 paper stated that zizanoic acid was present at less than 10% in the commercial vetiver oils before selective enrichment, reinforcing that it is a minor-to-moderate acid constituent rather than a dominant universal peak.
The same 2025 paper stated that zizanoic acid was present at less than 10% in the commercial vetiver oils before selective enrichment, reinforcing that it is a minor-to-moderate acid constituent rather than a dominant universal peak.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2004 Journal of Agricultural and Food Chemistry abstract on Brazilian vetiver oil described zizanoic acid as one of the main identified compounds and noted that removing this acid improved perfumery interest after conversion toward khusimol-related material.
A 2004 Journal of Agricultural and Food Chemistry abstract on Brazilian vetiver oil described zizanoic acid as one of the main identified compounds and noted that removing this acid improved perfumery interest after conversion toward khusimol-related material.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human safety trial, dermal maximum, or IFRA-style limit for isolated zizanoic acid was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Public benefit-facing statements for zizanoic acid were often secondary or review-level rather than directly supported by easily accessible primary pharmacology papers in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Industry database usage flags list the material conservatively and do not substitute for a dedicated toxicology dossier.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
carboxylic acid enriched fraction behavior
The clearest directly supported mechanism-level context is chemical rather than clinical: zizanoic acid behaves as a recoverable carboxylic-acid fraction within vetiver oil and can be selectively separated from the apolar sesquiterpene matrix using alkaline silica-based chromatography.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Direct isolated-compound pharmacology for zizanoic acid was harder to verify from primary open sources than its identity and analytical chemistry.
- No human clinical evidence specific to isolated zizanoic acid was located in this pass.
- Most practical safety language still has to be inferred from broader vetiver-oil context rather than from compound-specific toxicology monographs.
- No IFRA standard, RIFM monograph, or Tisserand & Young dermal limit specific to zizanoic acid (khusenic acid) was located; the previous dermal_limit_pct (5%) and phototoxic=false flag had no supporting citation and have been cleared pending verified data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.